Perspective Therapeutics (NYSE:CATX) Upgraded at Brookline Capital Management
Brookline Capital Management upgraded shares of Perspective Therapeutics (NYSE:CATX – Free Report) to a strong-buy rating in a research note published on Monday,Zacks.com reports. Brookline Capital Management also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($0.88) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.33) […]
Brookline Capital Management upgraded shares of Perspective Therapeutics (NYSE:CATX – Free Report) to a strong-buy rating in a research note published on Monday,Zacks.com reports. Brookline Capital Management also issued estimates for Perspective Therapeutics’ Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($0.88) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.33) […]
